|(G;G)||2||somewhat less likely to respond to certain antidepressants|
|(G;T)||2||somewhat more likely to respond to certain antidepressants|
|(T;T)||2||somewhat more likely to respond to certain antidepressants|
When treated for depression with substrates of the protein encoded by ABCB1, carriers of one or two minor alleles at these ABCB1 SNPs have been reported to respond better than non-carriers. The antidepressant drugs that are known to be substrates include citalopram, paroxetine, amitriptyline, and venlafaxine. The relative odds of better response for rs2235015(T) carriers is 7.72 (CI: 2.8-21.3, p=0.000065) based on a study of ~400 primarily Caucasian patients.10.1016/j.neuron.2007.11.017
The 9 SNPs in the linkage block identified are 10.1016/j.neuron.2007.11.017:
[PMID 18382661] Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample.
[PMID 18535201] A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose.
[PMID 21172166] Pharmacogenetics of antidepressant response.
[PMID 22641028] ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder.
|qualified_impact||Insufficiently evaluated pharmacogenetic|
[PMID 22672924] Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas